원바이오젠
Financials
Valuation Metrics
원바이오젠's Market Cap is ₩390B. At end of 2025 it was ₩474B. Ranked #1865 of 2,405 in KR market (top 78%), #1156 of 1,627 on KOSDAQ (top 71%), #77 of 94 in Health Care Equipment & Services (top 82%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 39.02B KRW | KR#1,865/2,405 Sec#77/94 |
| Revenue | 37.80B KRW | KR#1,935/2,405 Sec#59/94 |
| Net Income | 8.42B KRW | KR#1,028/2,405 Sec#29/94 |
| Total Assets | 53.88B KRW | KR#2,170/2,405 Sec#72/94 |
| Net Assets | 44.67B KRW | KR#1,972/2,405 Sec#65/94 |
| Employees | 72 | KR#1,856/2,405 Sec#74/94 |
| Value | ||
| P/E | 4.63x | KR#357/2,405 Sec#7/94 |
| P/B | 0.87x | KR#1,421/2,405 Sec#36/94 |
| PEG | 0.01x | KR#123/2,405 Sec#5/94 |
| P/S | 1.03x | KR#1,456/2,405 Sec#31/94 |
| EV/EBITDA | 4.30x | KR#207/2,405 Sec#5/94 |
| FCF Yield | 16.69% | KR#422/2,405 Sec#7/94 |
| Profitability | ||
| ROE | 18.85% | KR#197/2,405 Sec#7/94 |
| ROA | 15.63% | KR#108/2,405 Sec#7/94 |
| Op. Margin | 24.86% | KR#99/2,405 Sec#7/94 |
| Revenue Growth | 18.04% | KR#598/2,405 Sec#32/94 |
| Earnings Growth | 433.53% | KR#122/2,405 Sec#5/94 |
| Financial Health | ||
| Debt Ratio | 20.61% | KR#377/2,405 Sec#20/94 |
| Total Debt | 5.50B KRW | KR#1,762/2,405 Sec#63/94 |
| FCF | 6.51B KRW | KR#834/2,405 Sec#23/94 |
| Cash | 4.07B KRW | KR#2,077/2,405 Sec#81/94 |
| Current Ratio | 3.25x | KR#502/2,405 Sec#32/94 |
| Net Debt/EBITDA | 0.15x | KR#621/2,405 Sec#25/94 |
| Dividend | ||
| Div. Yield | 2.55% | KR#797/2,405 Sec#17/94 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | 10.00% | KR#438/2,405 Sec#10/94 |
| 1M Return | -7.56% | KR#947/2,405 Sec#36/94 |
| From 52W High | -34.52% | KR#566/2,405 Sec#17/94 |
| 1Y MDD | -37.33% | KR#470/2,405 Sec#11/94 |
| Trading | ||
| Volume | 5,439 shares | KR#2,070/2,405 Sec#84/94 |
| Trading Value | 30.1M KRW | KR#1,957/2,405 Sec#78/94 |
| Foreign Own. | 2.56% | KR#1,428/2,405 Sec#51/94 |
| Per Share | ||
| EPS | 1,187 KRW | KR#653/2,405 Sec#14/94 |
| BPS | 6,297 KRW | KR#1,333/2,405 Sec#31/94 |
Company Info
The company, established in 2006, was listed on the KOSDAQ market in 2021 through a reverse merger with Kyobo 8th Special Purpose Acquisition Company. It manufactures medical materials, wound dressings, biosensor patches, and cosmetics, primarily supplying polyurethane foam dressings and hydrocolloid dressings to hospitals and pharmacies. Driven by population aging and increasing plastic surgeries, the company is expanding its business into the wound dressing market and developing skin regeneration and functional cosmetics in the derma-cosmetic sector. WonBiogen was established in 2018 and is headquartered in Gumi-si, Gyeongsangbuk-do.